causes increased levels of plasma cell-free DNA as a result of cell death and tissue damage.
Objectives.-This study investigates plasma cell-free DNA concentrations in sickle cell disease patients, and aims at exploring the significance of plasma cell-free DNA as a potential biomarker in predicting its complications.
Design.-Plasma cell-free DNA levels were measured using real-time quantitative polymerase chain reaction to quantitatively measure b-globin gene in blood samples from 57 sickle cell disease patients with acute vasoocclusive crisis, 42 patients in steady state, 16 individuals with sickle cell trait, and 40 healthy controls.
Results.-Plasma cell-free DNA level was significantly elevated in samples from patients with acute vasoocclusive crisis when compared with those in steady state (P ¼ .002), and was significantly higher both in crisis and in steady state when compared with individuals with sickle cell trait and healthy controls (P , .001). There was no difference in cell-free DNA levels between individuals with sickle cell trait and healthy controls. There was no association between plasma cell-free DNA levels and various clinical complications of sickle cell disease and comorbidity.
Conclusions.-Plasma cell-free DNA, as quantified by polymerase chain reaction amplification of the b-globin and human telomerase reverse transcriptase genes, is increased in sickle cell disease patients in vasoocclusive crisis and in steady state compared with individuals with sickle cell trait and healthy controls, and may be used as a tool to diagnose and monitor the sickle cell crisis and differentiate post-packed red cell transfusion sickle cell disease patients from individuals with sickle cell trait.
(Arch Pathol Lab Med. 2014;138:678-683; doi: 10.5858/ arpa.2012-0725-OA) S ickle cell disease (SCD) is an inherited hematologic disorder caused by the intraerythrocytic polymerization of deoxyhemoglobin S, which deforms the shape of red blood cells and alters their ability to circulate, particularly in narrow vascular beds. 1, 2 Two major physiologic processes, shortened red blood cell survival and vaso-occlusion, account for most of the clinical manifestations of SCD, namely chronic hemolytic anemia and recurrent painful episodes.
2,3
Although the deoxygenation/polymerization/sickling process provides a basic understanding of SCD, there is an increasing appreciation that interactions of sickle cells with other cells and proteins contribute to hemolysis and vasoocclusion. 4 In 1947, Mandel and Metais 5 discovered the presence of circulating nucleic acids in plasma/serum. Later studies on circulating nucleic acids were mainly focused on autoimmune diseases. 6 The profound implication of circulating nucleic acids in diagnostic medicine became recognized only some 30 years later, when Leon et al 7 demonstrated elevated circulating cell-free nucleic acid levels in cancer patients when compared with healthy controls and a generally poorer survival of cancer patients with higher circulating nucleic acid level after therapies. This finding has opened up new avenues to use cell-free DNA (cfDNA) for noninvasive diagnosis and monitoring.
Although circulating cfDNA is present in the plasma of healthy subjects, it offers hope for noninvasive tests that can be extended to a variety of clinical situations, including SCD, 8 detection of fetal DNA in pregnant women for noninvasive prenatal diagnosis, 9 cancer, 7,10 autoimmune diseases, 11 and physical trauma.
12
In SCD, tissue damage and increased cell death occur as a result of the repetitive episodes of vascular occlusion and localized ischemia and the chronic low-grade inflammation. 13 The purpose of this study is to (1) test the hypothesis that levels of cfDNA are increased in the plasma of SCD patients in acute painful vaso-occlusive crisis (VOC) compared with steady state situation and to ethnically matched healthy controls, (2) correlate cfDNA levels with other biomarkers known to be elevated in acute sickling crises, and (3) explore the potential use of cfDNA as a biomarker in diagnosis and monitoring SCD and its complications, such as acute pain crisis.
MATERIALS AND METHODS

Patients and Controls
Subjects included 4 groups: (1) SCD patients admitted to the hospital with acute painful VOC, (2) SCD patients in steady state with no clinical evidence of acute VOC, (3) individuals with sickle cell trait, (4) healthy age-, sex-, and ethnicity-matched controls. The subjects were recruited from 2 major general hospitals in Kuwait: Mubarak Al-Kabeer Hospital and Al-Amiri Hospital. Blood samples were collected during a period of 7 months (December 2009-June 2010). The study was approved by the joint Research Ethics Committee of Kuwait University and Ministry of Health, and informed written consent was obtained from all patients and participants.
Blood samples were obtained from consenting patients if they were admitted into hospital in acute VOC, which is defined as an episode of acute pain in the limbs and/or abdomen, resulting in hospitalization, that cannot be explained by any medical problem other than SCD.
14 Samples were also obtained from consenting steady-state patients free of VOC who were visiting the specialist outpatient clinic. None of the patients had received blood products within 3 months of sample collection. Samples during acute VOC were taken within 24 hours of hospital admission. The total number of samples collected from SCD patients (n ¼ 99) was 112. Nine patients were studied during both VOC and steady state, and 10 patients provided repeated samples during separate episodes of VOC, including 4 patients who gave 1 sample during each of 3 separate VOC episodes and 6 patients who gave 1 sample during each of 2 separate VOC episodes. In all cases, biochemical and hematologic parameters were measured at the same time as part of the patients' routine care, including complete blood cell count, reticulocyte count (Beckman Coulter Hematology Analyzer, Beckman Coulter, Brea, California), lactate dehydrogenase, C-reactive protein (IMMAGE Immunochemistry System, Beckman Coulter), D-dimer (Taytec D-Dimer Latex Kit, Taytec Enterprises Inc, Mississanga, Ontario, Canada), soluble P-selectin (Human Soluble P-Selectin [sP-selectin] Platinum ELISA Kit, eBioscience, San Diego, California), and hemoglobin high-performance liquid chromatography analysis (Waters Corporation, Milford, Masachusetts). Clinical data regarding complications of SCD and other medical conditions or diseases in all patients were obtained from their medical charts. Hyposplenism was assessed by abdominal ultrasound and peripheral blood smear findings, osteoporosis was assessed by dual x-ray absorptiometry, cardiovascular complications were assessed by echocardiogram and multi-gated acquisition scan, hepatitis C virus infection was determined by detection of anti-hepatitis C virus antibodies and hepatitis C virus RNA by polymerase chain reaction (PCR), and renal impairment was assessed by measuring creatinine clearance.
Sample Collection
For all SCD patients, the peripheral venous blood was collected into 3 tubes (1 EDTA tube, 1 plain tube, and 1 sodium citrate tube) to measure the above-mentioned analytes. Measurement of plasma cfDNA was done on blood samples collected in EDTA tubes, which were centrifuged at 3500g for 10 minutes at room temperature within 2 hours of collection; the plasma was then aliquoted in microcentrifuge tubes and recentrifuged at 15 000g for 10 minutes at room temperature to remove any remaining cell debris. Then, the supernatant plasma was stored at À808C for further analysis. Blood from plain and sodium citrate tubes was centrifuged at 3500g for 10 minutes at room temperature, and then plasma and serum were carefully separated and stored at À808C for further analysis. For the sickle cell trait group and the control group, only 1 EDTA tube of peripheral venous blood was collected from each subject, and the plasma was then separated as mentioned earlier and stored at À808C for further analysis.
Sample Preparation and DNA Isolation From Plasma Sample
The QIAamp DNA Blood Mini Kit (Qiagen, Crawley, United Kingdom) was used for DNA purification. The procedure was performed using a standard microcentrifuge (spin protocol) and the QIAamp mini spin columns. A 400-lL plasma sample was first lysed using the Qiagen protease, which is free of DNAase and RNAase activity, and with buffering conditions (salts and pH) that allow the binding of only DNA to the QIAamp membrane, excluding proteins and other contaminants that can inhibit PCR. This was followed by washing steps using 2 different washing buffers, buffer AW1 and buffer AW2, to completely remove residual contaminants and improve the purity of the eluted DNA. Finally, purified DNA was eluted with buffer AE to allow the long-term storage of DNA at À208C. The concentration of the eluted DNA was spectrophotometrically measured by absorbance at 260 nm to determine the DNA yields. The purity of DNA was determined by calculating the ratio of absorbance at 260 nm to absorbance at 280 nm. A ratio of 1.7 to 1.9 indicates pure DNA.
DNA Quantification
Circulating DNA was quantified by real-time quantitative PCR using a PE Applied Biosystems 7900 HT Sequence Detector (Applied Biosystems, Warrington, United Kingdom). The quantitative assay was based on amplification of the b-globin gene using conditions, primer sequences, and probe sequences as previously described. 15 Amplification of the b-globin gene was performed using the following primers and probe sequences: forward: 5 0 -GTG CAC CTG ACT CCT GAG GAG A-3 0 , reverse: 5 0 -CCT TGA TAC CAA CCT GCC CAG-3 0 , and dual labeled fluorescent TaqMan probe:
The primer/probe combinations were designed using Primer Express Software (Perkin Elmer, Wathan, Massachusetts), and the sequence data were obtained from GenBank (accession No. U01317 [b-globin gene]). 15, 16 The PCR primers and probe were synthesized by Applied Biosystems. DNA amplifications were done in a 96-well plate. Each sample was analyzed in duplicate, and serial dilutions of human DNA were used and run in triplicate with each analysis to establish a calibration curve. A conversion factor of 3.3 pg of DNA per cell was used for the expression of results as copy numbers, and the mean quantity of each duplicate was used for further calculations. The results were expressed in copies per 5 lL, and were converted to genome equivalents per milliliter (GE/ mL) according to Lo et al. 15 The cfDNA was quantified to determine if sufficient DNA or PCR inhibitors were present in samples before b-globin gene amplification was performed, using the Quantifiler human DNA quantification kit (Applied Biosystems), which uses the 5 0 nuclease assay (real-time quantitative PCR) and TaqMan probe-based technology.
Data Analysis
Data were analyzed using IBM SPSS Statistics, version 19 (IBM, Armonk, New York). Quantitative variables were analyzed using descriptive statistics; means are reported with standard deviations and medians are reported with their interquartile ranges (25th and 75th percentiles) for parametric and nonparametric variables, respectively. Parametric and nonparametric measures of comparison were used for symmetric and skewed variables, respectively. Comparisons among the 4 groups (SCD patients with VOC, SCD patients in steady state, individuals with sickle cell trait, and healthy controls) were carried out using the Kruskal-Wallis test. The MannWhitney test was used for comparing any 2 groups in the study. The 9 patients who provided paired samples during acute VOC and steady state were studied using the Wilcoxon signed rank test, and were included in the analysis of their respective group and in the overall analysis. Analysis of repeat samples from the 10 patients who provided samples during 2 or 3 separate episodes of VOC was performed as separate data points. Spearman and Pearson correlation tests were performed to test correlations between plasma cfDNA levels and inflammatory, hemolytic, and coagulation activation markers and clinical parameters, as applicable.
Significance for main effects was tested at P , .05. The associations between plasma cfDNA and the clinical complications of SCD or intercurrent illnesses/diseases and hemoglobin F level were determined through logistic regression.
RESULTS
One hundred and twelve samples were collected during the study period from 57 SCD patients during 70 acute painful VOC episodes and from 42 SCD patients in steady state. Blood samples were also collected from 16 subjects with sickle cell trait and from 40 age-, sex-, and ethnicitymatched healthy control subjects. Descriptive data for the study cohort, individuals with sickle cell trait, and healthy controls are detailed in Table 1 .
Plasma cfDNA
In this study, cfDNA was estimated by 2 independent methods: amplifying the b-globin gene and using a quantitative PCR against the nontranslated region of human telomerase reverse transcriptase gene (hTERT), a gene that is not involved in hemoglobin. Plasma cfDNA concentration data were not normally distributed, and therefore the median and interquartile range were used to describe the data. Table 2 describes the plasma cfDNA levels for the 4 groups included in the study. The Kruskal-Wallis test revealed a significant difference in plasma cfDNA levels among the 4 groups of the study (P , .001). Plasma cfDNA concentrations were significantly elevated in acute VOC (median ¼ 12.16 GE/mL) when compared with steady state (median ¼ 6.54 GE/mL), with a P value of .002. DNA concentrations were significantly higher in VOC and in steady state when compared with healthy controls (P , .001). No significant difference was found between individuals with sickle cell trait (median ¼ 3.86 GE/mL) and healthy controls (median ¼ 3.62 GE/mL) ( Figure 1) . Eight (88.8%) of the 9 SCD patients who provided samples during both VOC and steady state showed increased plasma cfDNA concentrations in crisis (median ¼ 8.44 GE/mL) compared with steady state (median ¼ 8.67 GE/mL), with a P value of .04.
When comparing between 2 groups of patients, SCD patients in VOC and steady-state SCD patients, the results were the same as the comparison between VOC and steady state of the same patients: plasma cfDNA levels were significantly higher in SCD patients in VOC than in steadystate SCD patients (P ¼ .002).
Results Using the Quantifiler Human DNA Quantification Kit
There was a significant difference in plasma cfDNA levels between SCD patients in VOC and those in steady state (P ¼ .01). A significant difference was also detected between SCD patients in VOC and healthy controls (P , .001), and between SCD patients in steady state and healthy controls (P , .001); however, there was no significant difference between subjects with sickle cell trait and healthy controls (P ¼ .06). These data confirm the higher cfDNA in SCD patients in VOC compared with steady-state SCD and healthy controls using another target, namely the hTERT gene. There was a good correlation between cfDNA levels when both techniques were used (Figure 2 ).
There was a wide interindividual variation in cfDNA concentrations among patients in VOC, with overlap between steady-state and crisis groups (Figure 3 ).
Plasma cfDNA and Hematologic, Hemolytic, Inflammatory, and Coagulation Activation Markers
Mean plasma cfDNA levels of the 4 study groups were compared with the mean hemoglobin concentration values and serum soluble P-selectin levels; there was no positive correlation among any of the groups. The median plasma cfDNA level for each group was compared with median values of white blood cell count, lactate dehydrogenase, Ddimer, C-reactive protein, and reticulocyte count. Plasma cfDNA levels in SCD patients in crisis showed a significant correlation with white blood cell count (P ¼ .04), lactate dehydrogenase (P ¼ .004), and C-reactive protein (P , .001); however, no correlation was found with reticulocyte count (Table 3) . D-dimer levels showed a significant association with plasma cfDNA levels in SCD patients in crisis (P ¼ .05).
Plasma cfDNA and Hemoglobin S and Hemoglobin F Levels
No correlation was found between plasma cfDNA level and hemoglobin S levels (P ¼ .13), and there was no relationship between hemoglobin F levels and plasma cfDNA level among all studied SCD patients (P ¼ .97).
Plasma cfDNA and Clinical Complications
There was no significant association between plasma cfDNA levels in steady-state SCD patients and various chronic clinical complications of SCD, including organ damage and the frequency of VOC episodes (Table 4) .
COMMENT
Circulating nucleic acids in plasma/serum were discovered by Mandel and Metais 5 in 1947, and it was not until 1975 that Leon et al 6 were able to quantitate circulating plasma cfDNA. Later studies 7, 9, 12, 17 were mainly focused on using circulating cfDNA as a potentially useful diagnostic and prognostic marker in a variety of clinical conditions, including cancer, pregnancy, physical trauma, and solid organ transplant. This study shows that cfDNA level is increased in the plasma of SCD patients with acute painful episodes compared with levels during steady state. This increase is likely to result from increased liberation after acute tissue damage associated with vaso-occlusion. This possible mechanism is supported by the finding of positive correlation between plasma cfDNA concentrations and the other hematologic, hemolytic, inflammatory, and coagulation activation markers, including white blood cell count, lactate dehydrogenase, C-reactive protein, and D-dimers, which was in agreement with a previous report. 8 The present data suggest that cfDNA level may be useful for the diagnosis of acute sickle cell VOC, for which no reliable diagnostic test is currently available. It may also be a useful marker in clinical situations that pose diagnostic and management challenges in SCD patients presenting with complaints of pain, especially in patients with very frequent acute VOC episodes that could be triggered by drug-seeking behavior or dependency. Although our data showed a wide interindividual variation in cfDNA concentrations among patients in crisis, with overlap between steady-state and VOC groups, there are significant differences between the VOC and steady states in the same patients. Therefore, the same patient's baseline level of cfDNA in steady state is probably more useful for the diagnosis and monitoring of VOC than establishing a reference range for the steady state of SCD.
Although our study confirms the findings of previous studies, in which a wide range of plasma cfDNA levels was demonstrated among different patient groups, [6] [7] [8] [18] [19] [20] we also found that cfDNA levels were significantly different in patients with SCD during steady state when compared with individuals with sickle cell trait and healthy controls. These data may potentially be useful in clinical practice to differentiate post-packed red cell transfusion SCD patients from individuals with sickle cell trait, as such differentiation is currently based mainly on reliable transfusion history, which often is unknown or not available.
Several factors might explain or contribute to the wide range of plasma cfDNA levels in sickle cell patients with VOC, including (1) the extent of tissue damage during a crisis, which might vary from local to extensive; (2) severity (mild to severe), which varies among affected patients, affecting the level of several biomarkers in plasma, including cfDNA; (3) the preanalytic and analytic factors, which include the timing of blood draw following the onset of pain and the release of cfDNA from white blood cells in the blood sample during and after collection 8, 20 ; (4) a poorly understood physiologic mechanism by the liver and kidney that might play a role in clearing the continuously released circulating cfDNA 21 ; (5) the variability in pain tolerance among affected patients, which makes it difficult to determine whether the patient is in steady state or in a mild VOC crisis that can be managed at home 8 ; and (6) the patient's genotype, which affects disease severity. [22] [23] [24] In this study, cfDNA was estimated by 2 methods: by amplifying the b-globin gene, and by using Quantifiler PCR, which quantitates the nontranslated region of hTERT, a gene that is not involved in hemoglobin. The Quantifiler PCR determines the amount of amplifiable DNA present in a sample, and provides a more accurate prediction of the amount of input DNA required for optimal PCR amplification. Optimizing sample DNA input improves the quality of genotypes, reducing repeat analysis. In addition, the Quantifiler PCR amplifies a spiked nonhuman sequence to detect any possible inhibition of the PCR process. Our method, therefore, quantitates cfDNA in 2 ways, avoiding issues of amplification inhibition because of hemoglobin gene mutations, polymorphisms, or other confounding factors. No quantification was performed in the previous study of cfDNA in SCD. 8 Because D-dimer level has been previously shown to be elevated in acute crises, a similar approach to improve the sensitivity and specificity of cfDNA is the concomitant measurement of D-dimer levels to diagnose and monitor acute VOC. 25 The present data did not show an association between plasma cfDNA levels and various clinical complications/ intercurrent illnesses in SCD patients, including end organ damage. In light of these findings, plasma cfDNA might be a potentially useful biomarker for diagnosis of VOC. It may also have a role in monitoring the resolution of crisis episodes, although further study of serial measurements during VOC is needed.
In conclusion, our study has shown that SCD patients in acute VOC state have a significant increase in the plasma levels of cfDNA of b-globin gene when compared with SCD patients in steady state, individuals with sickle cell trait, and healthy controls, which indicates that there is a potential usefulness of cfDNA of b-globin gene as a biomarker in diagnosing and monitoring the progress of VOC. Because of this study's small sample size and because it was limited to a single institution, further study to evaluate the clinical usefulness of cfDNA of b-globin gene is warranted. 
